Published in J Am Soc Nephrol on August 30, 2012
Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev (2013) 1.47
Indole 3-acetic acid, indoxyl sulfate and paracresyl-sulfate do not influence anemia parameters in hemodialysis patients. BMC Nephrol (2017) 1.40
Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia. J Am Soc Nephrol (2015) 1.16
Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int (2016) 1.00
Kidney pericytes: roles in regeneration and fibrosis. Semin Nephrol (2014) 0.95
Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients. Kidney Int (2015) 0.93
HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. Nat Rev Nephrol (2015) 0.92
Anemia and iron deficiency in COPD patients: prevalence and the effects of correction of the anemia with erythropoiesis stimulating agents and intravenous iron. BMC Pulm Med (2014) 0.88
Hypoxia Signaling Cascade for Erythropoietin Production in Hepatocytes. Mol Cell Biol (2015) 0.85
Ferric pyrophosphate citrate (Triferic™) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients. Nephrol Dial Transplant (2015) 0.84
Does erythropoietin slow progression of chronic kidney disease? J Renal Inj Prev (2013) 0.83
Clinical impact of hospital-acquired anemia in association with acute kidney injury and chronic kidney disease in patients with acute myocardial infarction. PLoS One (2013) 0.83
Hepcidin as a predictive factor and therapeutic target in erythropoiesis-stimulating agent treatment for anemia of chronic disease in rats. Haematologica (2014) 0.83
Estimating glomerular filtration rate in older people. Biomed Res Int (2014) 0.83
The A736V TMPRSS6 polymorphism influences hepcidin and iron metabolism in chronic hemodialysis patients: TMPRSS6 and hepcidin in hemodialysis. BMC Nephrol (2013) 0.82
International Comparisons to Assess Effects of Payment and Regulatory Changes in the United States on Anemia Practice in Patients on Hemodialysis: The Dialysis Outcomes and Practice Patterns Study. J Am Soc Nephrol (2015) 0.81
Iron Balance and the Role of Hepcidin in Chronic Kidney Disease. Semin Nephrol (2016) 0.80
Glomerular filtration rate in the elderly and in the oldest old: correlation with frailty and mortality. Age (Dordr) (2014) 0.80
Predictor of cardiovascular risks in end stage renal failure patients on maintenance dialysis. Pak J Med Sci (2016) 0.79
Recent advances in the management of hemodialysis patients: a focus on cardiovascular disease. F1000Prime Rep (2014) 0.78
Longitudinal changes in hematocrit in hypertensive chronic kidney disease: results from the African-American Study of Kidney Disease and Hypertension (AASK). Nephrol Dial Transplant (2015) 0.78
Association of Serum Erythropoietin With Cardiovascular Events, Kidney Function Decline, and Mortality: The Health Aging and Body Composition Study. Circ Heart Fail (2016) 0.77
Association of Increased Serum Leptin with Ameliorated Anemia and Malnutrition in Stage 5 Chronic Kidney Disease Patients after Parathyroidectomy. Sci Rep (2016) 0.77
Increased Synthesis of Liver Erythropoietin with CKD. J Am Soc Nephrol (2016) 0.76
Effects of carnitine on oxidative stress response to intravenous iron administration to patients with CKD: impact of haptoglobin phenotype. BMC Nephrol (2015) 0.75
Management of anemia in patients with diabetic kidney disease: A consensus statement. Indian J Endocrinol Metab (2016) 0.75
Administration of a High-Dose Erythropoietin-Stimulating Agent in Hemodialysis Patients is Associated with Late Arteriovenous Fistula Failure. Yonsei Med J (2017) 0.75
Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice. Am J Physiol Renal Physiol (2016) 0.75
[Blood count results from hypertensive patients seen in laboratory of CHU-HJRB Antananarivo in 2013]. Pan Afr Med J (2016) 0.75
Laboratory Profiles of Patients on Hemodialysis - A Retrospective One Year Study in a Rural Tertiary Care Hospital. J Clin Diagn Res (2015) 0.75
Bone Marrow-Derived Progenitor Cells Are Functionally Impaired in Ischemic Heart Disease. J Cardiovasc Transl Res (2016) 0.75
Increased serum hepcidin contributes to the anemia of chronic kidney disease in a murine model. Haematologica (2016) 0.75
Hemoglobin levels and blood transfusion in patients with sepsis in Internal Medicine Departments. BMC Infect Dis (2016) 0.75
Cardiorenal syndrome type 4: A study of cardiovascular diseases in chronic kidney disease. Indian Heart J (2016) 0.75
Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor. Clin Drug Investig (2016) 0.75
Effect of systemic inflammation on level of ferritin seminal in chronic renal male patient undergoing hemodialysis. Int Arch Med (2014) 0.75
The Prevalence and Management of Anemia in Chronic Kidney Disease Patients: Result from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD). J Korean Med Sci (2017) 0.75
Renal Denervation Improves the Baroreflex and GABA System in Chronic Kidney Disease-induced Hypertension. Sci Rep (2016) 0.75
Comparison of Hemoglobin Levels Before and After Hemodialysis and Their Effects on Erythropoietin Dosing and Cost. Nephrourol Mon (2016) 0.75
Renal Cell Protection of Erythropoietin beyond Correcting The Anemia in Chronic Kidney Disease Patients. Cell J (2013) 0.75
A look at risk factors of proteinuria in subjects without impaired renal filtration function in a general population in Owerri, Nigeria. Pan Afr Med J (2016) 0.75
Pentoxifylline for Anemia in Chronic Kidney Disease: A Systematic Review and Meta-Analysis. PLoS One (2015) 0.75
Hemoglobin discriminates stages of chronic kidney disease in elderly patients. Exp Ther Med (2015) 0.75
Interpretation of Erythropoietin and Haemoglobin Levels in Patients with Various Stages of Chronic Kidney Disease. J Med Biochem (2017) 0.75
Diagnostic utility of immunochemical fecal occult blood tests to detect lower gastrointestinal lesions in patients with chronic kidney disease. Int J Colorectal Dis (2015) 0.75
Anemia: A significant cardiovascular mortality risk after ST-segment elevation myocardial infarction complicated by the comorbidities of hypertension and kidney disease. PLoS One (2017) 0.75
Abnormal amyloid β42 expression and increased oxidative stress in plasma of CKD patients with cognitive dysfunction: A small scale case control study comparison with Alzheimer's disease. BBA Clin (2017) 0.75
Trace element and vitamin concentrations in paediatric dialysis patients. Pediatr Nephrol (2017) 0.75
Does Selection and Management of Patients with Chronic Kidney Disease In Government Run and Private Hospitals Differ? J Clin Diagn Res (2017) 0.75
Efficacy and safety of subcutaneous administration of lyophilized powder of alfa-erythropoietin to maintain hemoglobin concentrations among hemodialysis patients. Int J Nephrol Renovasc Dis (2017) 0.75
Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science (2004) 19.19
Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med (2006) 17.55
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med (1998) 11.58
A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem (2000) 8.52
Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem (2000) 8.39
Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med (1987) 5.57
Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med (2010) 5.48
Immunoassay for human serum hepcidin. Blood (2008) 5.32
KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis (2006) 5.28
LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett (2000) 5.22
Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int (2009) 4.61
Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature (1985) 4.23
Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet (1986) 4.04
Role of the kidney in erythropoiesis. Nature (1957) 3.75
Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int (2008) 3.34
Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A (1985) 3.28
Purification of human erythropoietin. J Biol Chem (1977) 2.83
Hepcidin--a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol (2009) 2.61
Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood (2010) 2.60
Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol (2005) 2.06
A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int (1996) 1.70
Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats. Blood (2011) 1.63
Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation. Blood (2011) 1.61
Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron (1998) 1.60
Humoral regulation of red cell production. Blood (1953) 1.60
Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol (2012) 1.52
Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization. Haematologica (2009) 1.51
Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis (2010) 1.43
Erythropoiesis in patients with renal failure undergoing chronic dialysis. N Engl J Med (1967) 1.41
The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int (1989) 1.28
Radioimmunoassay of erythropoietin: circulating levels in normal and polycythemic human beings. J Lab Clin Med (1982) 1.20
Immunoreactive erythropoietin in serum. I. Evidence for the validity of the assay method and the physiological relevance of estimates. Br J Haematol (1982) 1.19
Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney Int (1984) 1.11
Red blood cell survival in long-term dialysis patients. Am J Kidney Dis (2011) 1.06
An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin Nephrol (1997) 0.97
Intersecting guidelines: administering erythropoiesis-stimulating agents to chronic kidney disease patients with cancer. Semin Dial (2008) 0.82
The heterogeneity of circulating human serum erythropoietin. Endocrinology (1988) 0.80
An immunological cross-reactant of erythropoietin in serum which may invalidate EPO radioimmunoassay. Br J Haematol (1989) 0.79
Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet (2006) 8.32
Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol (2007) 8.08
BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet (2009) 4.84
Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med (2013) 4.14
Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest (2007) 4.09
Differential regulation of myeloid leukemias by the bone marrow microenvironment. Nat Med (2013) 2.48
Repulsive guidance molecule (RGMa), a DRAGON homologue, is a bone morphogenetic protein co-receptor. J Biol Chem (2005) 2.07
Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin. Blood (2008) 2.01
DRAGON, a bone morphogenetic protein co-receptor. J Biol Chem (2005) 1.89
Divergent roles of Smad3 and PI3-kinase in murine adriamycin nephropathy indicate distinct mechanisms of proteinuria and fibrogenesis. Kidney Int (2012) 1.66
DRAGON: a member of the repulsive guidance molecule-related family of neuronal- and muscle-expressed membrane proteins is regulated by DRG11 and has neuronal adhesive properties. J Neurosci (2004) 1.64
Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats. Blood (2011) 1.63
Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol (2012) 1.52
Bone morphogenetic protein signaling is impaired in an HFE knockout mouse model of hemochromatosis. Gastroenterology (2009) 1.51
Selective modulation of TLR4-activated inflammatory responses by altered iron homeostasis in mice. J Clin Invest (2009) 1.48
Repulsive guidance molecule RGMa alters utilization of bone morphogenetic protein (BMP) type II receptors by BMP2 and BMP4. J Biol Chem (2007) 1.45
Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis (2010) 1.43
BMP signaling mediated by ALK2 in the visceral endoderm is necessary for the generation of primordial germ cells in the mouse embryo. Genes Dev (2004) 1.40
Statement of concern about a commercial assay used to measure soluble hemojuvelin in humans. Am J Nephrol (2012) 1.31
The liver: conductor of systemic iron balance. Blood (2013) 1.30
BMP6 treatment compensates for the molecular defect and ameliorates hemochromatosis in Hfe knockout mice. Gastroenterology (2010) 1.22
The RGM/DRAGON family of BMP co-receptors. Cytokine Growth Factor Rev (2009) 1.21
Regulation of TMPRSS6 by BMP6 and iron in human cells and mice. Blood (2011) 1.19
Aquaporin 2 (AQP2) and vasopressin type 2 receptor (V2R) endocytosis in kidney epithelial cells: AQP2 is located in 'endocytosis-resistant' membrane domains after vasopressin treatment. Biol Cell (2006) 1.14
Evidence for a role of transforming growth factor (TGF)-beta1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-beta type II receptor. Diabetes (2007) 1.11
Dragon (repulsive guidance molecule b) inhibits IL-6 expression in macrophages. J Immunol (2010) 1.08
The bone morphogenetic protein-hepcidin axis as a therapeutic target in inflammatory bowel disease. Inflamm Bowel Dis (2011) 1.05
The molecular pathogenesis of hereditary hemochromatosis. Semin Liver Dis (2011) 1.03
Downregulation of the vasopressin type 2 receptor after vasopressin-induced internalization: involvement of a lysosomal degradation pathway. Am J Physiol Cell Physiol (2005) 1.01
Innate response activator B cells aggravate atherosclerosis by stimulating T helper-1 adaptive immunity. Circulation (2014) 0.99
Functional role of the NPxxY motif in internalization of the type 2 vasopressin receptor in LLC-PK1 cells. Am J Physiol Cell Physiol (2003) 0.99
Dragon enhances BMP signaling and increases transepithelial resistance in kidney epithelial cells. J Am Soc Nephrol (2010) 0.98
Iron regulation of hepcidin despite attenuated Smad1,5,8 signaling in mice without transferrin receptor 2 or Hfe. Gastroenterology (2011) 0.98
Reconstitution and analysis of soluble inhibin and activin receptor complexes in a cell-free system. J Biol Chem (2004) 0.95
Phosphorylation of threonine 276 in Smad4 is involved in transforming growth factor-beta-induced nuclear accumulation. Am J Physiol Cell Physiol (2003) 0.95
Altered hepatic BMP signaling pathway in human HFE hemochromatosis. Blood Cells Mol Dis (2010) 0.93
Localization and action of Dragon (repulsive guidance molecule b), a novel bone morphogenetic protein coreceptor, throughout the reproductive axis. Endocrinology (2005) 0.93
Hepcidin regulation by BMP signaling in macrophages is lipopolysaccharide dependent. PLoS One (2012) 0.91
Repulsive guidance molecule (RGM) family proteins exhibit differential binding kinetics for bone morphogenetic proteins (BMPs). PLoS One (2012) 0.91
The BMP coreceptor RGMb promotes while the endogenous BMP antagonist noggin reduces neurite outgrowth and peripheral nerve regeneration by modulating BMP signaling. J Neurosci (2011) 0.90
BMP antagonists enhance myogenic differentiation and ameliorate the dystrophic phenotype in a DMD mouse model. Neurobiol Dis (2010) 0.89
A novel validated enzyme-linked immunosorbent assay to quantify soluble hemojuvelin in mouse serum. Haematologica (2012) 0.88
Effects of the renal medullary pH and ionic environment on vasopressin binding and signaling. Kidney Int (2008) 0.88
A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats. Nephrol Dial Transplant (2013) 0.88
Differential actions of follistatin and follistatin-like 3. Mol Cell Endocrinol (2004) 0.87
Alix (AIP1) is a vasopressin receptor (V2R)-interacting protein that increases lysosomal degradation of the V2R. Am J Physiol Renal Physiol (2007) 0.86
In the absence of type III receptor, the transforming growth factor (TGF)-beta type II-B receptor requires the type I receptor to bind TGF-beta2. J Biol Chem (2004) 0.83
Exogenous BMP7 corrects plasma iron overload and bone loss in Bmp6-/- mice. Int Orthop (2014) 0.81
Dragon (repulsive guidance molecule RGMb) inhibits E-cadherin expression and induces apoptosis in renal tubular epithelial cells. J Biol Chem (2013) 0.80
The soluble transforming growth factor-beta receptor: advantages and applications. Int J Biochem Cell Biol (2008) 0.79
BMP signaling modulates hepcidin expression in zebrafish embryos independent of hemojuvelin. PLoS One (2011) 0.79
Visualizing microtubule-dependent vasopressin type 2 receptor trafficking using a new high-affinity fluorescent vasopressin ligand. Endocrinology (2011) 0.77
Heterologous downregulation of vasopressin type 2 receptor is induced by transferrin. Am J Physiol Renal Physiol (2012) 0.76
BuMPing iron with modified heparins. Blood (2014) 0.75